Evidence map›Paper›PMID 31404304›Full record

ArticleOncology letters2019

Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3

Michele Massimino, Stefania Stella, Elena Tirrò, Maria Letizia Consoli, Maria Stella Pennisi, Adriana Puma, Silvia Rita Vitale, Chiara Romano, Valentina Zammit, Fabio Stagno and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. The silent players: AtypicalOncology reports · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michele MassiminoDepartment of Clinical and Experimental Medicine, University of Catania, Catania I-95123, Italy.
Stefania StellaDepartment of Clinical and Experimental Medicine, University of Catania, Catania I-95123, Italy.
Elena TirròDepartment of Clinical and Experimental Medicine, University of Catania, Catania I-95123, Italy.
Maria Letizia ConsoliDivision of Hematology and Bone Marrow Transplant, A.O.U. Policlinico-Vittorio Emanuele, Catania I-95123, Italy.
Maria Stella PennisiDepartment of Clinical and Experimental Medicine, University of Catania, Catania I-95123, Italy.
Adriana PumaDepartment of Clinical and Experimental Medicine, University of Catania, Catania I-95123, Italy.
Silvia Rita VitaleDepartment of Clinical and Experimental Medicine, University of Catania, Catania I-95123, Italy.
Chiara RomanoDepartment of Clinical and Experimental Medicine, University of Catania, Catania I-95123, Italy.
Valentina ZammitDivision of Hematology and Bone Marrow Transplant, A.O.U. Policlinico-Vittorio Emanuele, Catania I-95123, Italy.
Fabio StagnoDivision of Hematology and Bone Marrow Transplant, A.O.U. Policlinico-Vittorio Emanuele, Catania I-95123, Italy.
Francesco Di RaimondoDivision of Hematology and Bone Marrow Transplant, A.O.U. Policlinico-Vittorio Emanuele, Catania I-95123, Italy.
Livia ManzellaDepartment of Clinical and Experimental Medicine, University of Catania, Catania I-95123, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of chronic myeloid leukemia in a 52-year-old male expressing a rare e14a3

Indexed as

BCR-ABL1case reportchronic myeloid leukemiae14a3nilotinib

Identifiers

PMID31404304
PMCPMC6676706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.